| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61c0b38c0948cdbce0b193c5279ab4a9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-529 |
| filingDate |
1994-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1999-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ca49bef10827b96ec0def4b5d0b01da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acf6ad5933e1a24e22287184cdc93c01 |
| publicationDate |
1999-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2130776-C1 |
| titleOfInvention |
Pyrazolepyrimidinones for treatment of impotents |
| abstract |
FIELD: organic chemistry, medicine. SUBSTANCE: invention proposes new agent and a method of treatment or prophylaxis of erectile disorder in male animal involving man and for treatment or prophylaxis or sexual disorder in female. The first agent, for example, the compound of the general formula (I): where radical values are indicated in the invention claims or its pharmaceutically acceptable salts or a pharmaceutical composition containing this compound which is an inhibitor of cGMP phosphodiesterase. The indicated agent is designated for intake by patient by per os route first. The compound of the general formula (I) or its pharmaceutically acceptable salts or a pharmaceutical composition containing this compound is proposed as an agent and a method of treatment or prophylaxis of sexual disorder in female. EFFECT: broadened pattern of agents of the indicated prescription. 14 cl |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8669242-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8653051-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2463054-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006110120-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9211334-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8648060-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9192669-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10441592-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9737548-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9333203-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9597335-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10314848-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8575139-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9700566-B2 |
| priorityDate |
1993-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |